Journal of Fertility Biomarkers invites researchers, clinicians, and laboratory scientists to submit original manuscripts advancing the science of reproductive biomarkers. We publish studies spanning hormonal assessments, genetic markers, metabolomic profiles, imaging biomarkers, and novel diagnostic tools that improve fertility care outcomes.

Our editorial focus emphasizes rigorous methodology, transparent reporting, and clinical applicability. We welcome submissions from academic centers, clinical practices, and industry collaborators working to translate biomarker discoveries into patient benefit.

Journal of Fertility Biomarkers invites high quality submissions that advance biomarker discovery, validation, and clinical translation in reproductive medicine. We welcome original research, systematic reviews, clinical trials, and translational studies that improve fertility assessment and treatment outcomes.

Our editorial focus prioritizes rigorous assay validation, transparent reporting, and actionable insights for clinical fertility care.

• Ovarian reserve biomarkers (AMH, FSH, AFC) and reproductive aging
• Male factor biomarkers including semen analysis and DNA fragmentation
• Endometrial receptivity and implantation biomarkers
• Embryo viability and selection biomarkers, including morphokinetics
• Noninvasive biomarkers from follicular fluid or spent media
• Proteomics, metabolomics, genomics, and multi omics approaches
• Inflammatory, immune, and microbiome biomarkers in fertility care
• Biomarkers for PCOS, endometriosis, and unexplained infertility
• Fertility preservation and oncofertility biomarker studies
• Predictive models for ART response and treatment personalization
• Biomarkers for ovarian stimulation and luteal phase support
• Clinical outcomes including implantation, pregnancy, and live birth

Studies addressing biomarker validation, assay standardization, and clinical decision thresholds are particularly encouraged. We value research that bridges laboratory findings with real-world fertility practice, including cost-effectiveness analyses and implementation studies.

Authors investigating novel biomarker combinations, machine learning prediction models, or point-of-care testing platforms are invited to submit their work. We also welcome studies examining biomarker performance across diverse patient populations and clinical settings.

• Clinical cohort studies with defined outcomes
• Protocol papers for assay validation and biomarker reproducibility
• Data resource reports that enable reuse or benchmarking
• Technical notes on laboratory or imaging methods

JFB prioritizes manuscripts that advance diagnostic accuracy, predictive modeling, or treatment optimization through biomarker integration. We encourage authors to provide detailed assay validation, sample collection protocols, and outcome definitions that support reproducibility.

Successful submissions present a clear clinical question, robust assay methodology, and transparent reporting of outcomes. We value studies that connect biomarker signals to clinical decision making in fertility care.

Authors should document sample timing, assay validation, and outcome definitions to support reproducibility and clinical relevance.

• Clear inclusion and exclusion criteria with diagnosis detail
• Validated biomarkers or imaging criteria
• Appropriate statistical analysis and confounder control
• Interpretation aligned with clinical practice implications

Published articles receive permanent DOI assignment, indexing submission to major databases, and social media promotion through journal channels. Authors retain copyright under Creative Commons licensing, enabling broad dissemination and reuse of their work.

JFB maintains relationships with fertility societies and research networks to maximize article visibility. We provide usage statistics and altmetric tracking to help authors demonstrate research impact.

JFB maintains efficient editorial workflows to minimize time from submission to publication while preserving rigorous peer review standards. Our editorial team includes specialists in reproductive endocrinology, embryology, andrology, and biomarker validation.

Submissions undergo editorial screening for scope fit, methodological rigor, and reporting completeness. Qualified manuscripts move to single blind peer review with subject matter experts.

Open access publishing ensures that fertility biomarker research reaches clinicians, embryologists, laboratory scientists, and patients worldwide without subscription barriers. All accepted articles are immediately available under Creative Commons licensing.

JFB operates under an open access model to ensure fertility biomarker evidence is discoverable and reusable. APCs are applied after acceptance and support peer review, production, and archiving services.

Membership options and affordable APC waivers are available for eligible authors. Contact the editorial office at [email protected] for guidance.

JFB adheres to international publishing ethics guidelines including COPE recommendations and ICMJE requirements. All submissions undergo plagiarism screening using iThenticate software. Authors must disclose conflicts of interest, funding sources, and author contributions.

Research involving human subjects requires ethics committee approval and informed consent documentation. Animal studies must follow institutional guidelines and report humane care standards. Clinical trials require prospective registration in recognized databases such as ClinicalTrials.gov or equivalent registries.

Data sharing is encouraged and authors should provide data availability statements. We support deposition of datasets in recognized repositories and encourage sharing of analysis code and protocols to enhance reproducibility.

Manuscripts should be prepared in Microsoft Word format with continuous line numbering. Figures should be submitted as separate high-resolution files in TIFF, PNG, or EPS format. Tables should be editable and placed at the end of the manuscript document.

Authors should follow the ICMJE recommendations for authorship criteria. All listed authors must have made substantial contributions to conception, design, data acquisition, analysis, or interpretation. Ghost authorship and honorary authorship are prohibited.

Cover letters should briefly describe the manuscript novelty, confirm that the work has not been published elsewhere, and identify any potential conflicts of interest. Suggested reviewers may be provided but final selection remains with the editorial team.

Authors frequently ask about manuscript preparation, submission requirements, and editorial processes. The following questions address common inquiries received by our editorial office.

Journal of Fertility Biomarkers serves the global reproductive medicine community by publishing high-quality evidence on diagnostic and prognostic biomarkers. Our editorial standards emphasize transparency, reproducibility, and clinical relevance across all manuscript types.

JFB is committed to rigorous, transparent publishing in fertility biomarker research and reproductive medicine. We emphasize reproducible laboratory methods, clear reporting of diagnostic criteria, and ethical compliance across all article types.

The editorial office supports authors, editors, and reviewers with clear guidance and responsive communication. For questions about scope or workflow, contact [email protected].

We encourage continuous improvement in reporting practices and share updates that help the community maintain high standards in biomarker validation, reproductive outcomes, and translational fertility science.